Acute Leukemia Stem Cell Therapy Development

Acute leukemia (AL) is a malignant clonal disease of hematopoietic stem cells. It occurs when abnormal primitive and naive cells (leukemia cells) proliferate in the bone marrow, accumulate in the bone marrow and inhibit normal hematopoiesis. With the development of medical technology, the treatment of acute leukemia is constantly innovating. Currently, CD BioSciences is offering acute leukemia stem cell therapy development services to facilitate the development of treatments for this disease.

Classification of Acute Leukemia

According to the kind of lesion cells, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) can be divided. The patient's disease staging, stage, and extent should be taken into account while developing a personalized treatment plan for acute leukemia.

• Acute lymphoblastic leukemia (ALL), a form of blood cancer, begins in white blood cells in the soft interior of your bones, or bone marrow. Systemic chemotherapy is the mainstay of treatment for this condition, however alternative options for treatment include targeted therapy, biological immunotherapy, and hematopoietic stem cell transplantation.

• The hazardous and frequently fatal condition known as acute myeloid leukemia (AML) affects the myeloid hematopoietic stem cells. The two main treatments for acute myeloid leukemia include chemotherapy and hematopoietic stem cell transplantation.

Molecular Targeting in Acute Myeloid Leukemia

• Targeting FLT3 Signaling Pathway
  A surface receptor is FLT3. When the FLT3 ligand engages the wildtype receptor, a series of subsequent events signal cell proliferation. This is accomplished first by the receptor's tyrosine residues being auto phosphorylated, followed by the phosphorylation and activation of the RAS, Src/JAK (Janus kinase), and PI3K pathways. One of the most common mutations found in AML, mutations of the FLT3 receptor are found in almost one- third of patients.

Activation of transcription with proliferation, survival and malignant transformation. (Lim, S. H. et al. 2017)

• Epigenetics in AML
  Lysine methyltransferases (KMTs) are responsible for mediating histone lysine methylation. In AML, the mixed-lineage leukemia (MLL) protein exhibits persistent molecular abnormalities. Hox expression is increased by the MLL protein, which prevents hematopoietic differentiation. Gene duplication or translocation causes the abnormal fusion proteins to form. The DOT1L protein, a KMT targeting H3K79, is frequently present in the abnormal MLL resulting from translocation.
• Targeting BCL-2 and JAK/STAT Pathway
  An anti-apoptotic protein known as BCL-2 has been shown to cause chemoresistance and its overexpression has been linked to AML. Another molecular therapeutic option is to target the JAK/STAT pathway, as JAK mutation has been linked to some AML patients. Clinical trials using JAK/STAT inhibitors and BCL-2 inhibitors are currently being conducted, and preliminary results are promising.

Our Services

CD BioSciences offers acute leukemia stem cell therapy development services. Chemotherapy is currently the primary treatment for leukemia, but its damage to normal cells limits its application. The inadequacy of chemotherapy alone can be overcome by stem cell transplantation.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Lim, S. H. et al. (2017). Molecular targeting in acute myeloid leukemia. Journal of Translational Medicine. 15(1), 183.